Home>Topics>Stocks>NPS Pharmaceuticals

NPS Pharmaceuticals NPSP

  1. All
  2. Commentary
  3. Headlines
    1. Shire considering bid for NPS Pharmaceuticals - Bloomberg

      Headlines

      Wed, 17 Dec 2014

      Dec 17 (Reuters) - Dublin-based Shire Plc, whose proposed sale to AbbVie Inc fell apart in October, is considering an offer for U.S-based drug developer NPS Pharmaceuticals Inc, Bloomberg reported, citing people familiar with the matter.

    2. FDA extends review date for NPS Pharma hormone replacement therapy

      Headlines

      Thu, 23 Oct 2014

      Oct 23 (Reuters) - NPS Pharmaceuticals Inc said the U.S. Food and Drug Administration had extended the review date for its hormone replacement therapy by three months to provide time for a full...

    3. Five Things You Should Know About U.S. Small-Caps

      Headlines

      Mon, 20 Oct 2014

      NPS Pharmaceuticals NPSP raised $50 million Monday through the sale of its Preotact royalty stream to Drug Royalty Corporation. We're maintaining our

    4. Sell-Off in Health Care Sector Overlooks Strong Fundamentals

      Headlines

      Fri, 25 Apr 2014

      Pharmaceuticals International, Inc. (U.S. Shares) (2.19%), AstraZeneca PLC (ADR) (1.78%) and NPS Pharmaceuticals , Inc. (1.74%). There are no assurances that any Janus portfolio currently holds these securities or other

    5. FDA staff says NPS Pharma's bowel drug needs no safety restrictions

      Headlines

      Fri, 12 Oct 2012

      (Reuters) - U.S. drug reviewers found three serious concerns related to NPS Pharmaceuticals Inc's experimental drug for short bowel syndrome but said they did not think the drug needed to be...

    6. Dropping Coverage of NPS Pharma

      Commentary

      Mon, 3 Aug 2009

      We are no longer providing equity research on NPS Pharma NPSP . We provide broad coverage of more than 1,800 companies across 91 industry groups and adjust our coverage as necessary based on client demand and investor interest.

    7. NPS Pharma's Fair Value Unchanged

      Commentary

      Fri, 12 Jun 2009

      We're maintaining our fair value estimate for NPS Pharmaceuticals NPSP following the release of positive Phase III data for Gattex (teduglutide) for short bowel syndrome. The outcome is consistent

    8. Maintaining NPS Pharma's Fair Value

      Commentary

      Tue, 5 May 2009

      We're maintaining NPS Pharmaceuticals ' NPSP fair value estimate following an uneventful first-quarter earnings report. The company has a manageable cash burn rate and continues

    9. NPS Pharma's Earnings Preview

      Commentary

      Mon, 9 Feb 2009

      As we approach NPS Pharmaceuticals ' NPSP fourth-quarter earnings report, we're looking for continued strong royalty revenue from Amgen AMGN and tight management of

    10. NPS Pharma Loses CEO

      Commentary

      Wed, 27 Feb 2008

      NPS Pharmaceuticals ' NPSP loss of CEO Tony Coles to Onyx Pharmaceuticals ONXX, announced Tuesday, does not affect our fair value estimate for NPS. The

    « Prev123Next »
    Content Partners